Connecticut Magazine recognizes Yale Cancer Center and Smilow Cancer Hospital physicians as 'Best Doctors'
Connecticut Magazine has named 77 Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven physicians and surgeons to its 2018 Best Doctors guide. Published in the magazine's April issue, the Best Doctors list consists of 779 Connecticut physicians from 78 medical specialties.
How Incarceration Raises Risk of Cancer Diagnosis and Death—Even After Release
The United States has one of the highest incarceration rates in the world, with nearly 2 million people in the criminal justice system facing potential barriers to accessing timely, quality care. Now, Yale researchers are finding that individuals with a history of incarceration are more likely to be diagnosed with cancer and are less likely to survive the disease.
Multidisciplinary COPPER Center Brings a Public Health Lens to Cancer Care
Studying cancer treatment outcomes is the mission of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, a collaborative effort of the Yale Cancer Center and the Schools of Medicine and Public Health.Source: Yale Public Health magazine
Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC
Roy S. Herbst, MD, PhD, ensign professor of medicine, medical oncology, professor, pharmacology, director, Center for Thoracic Cancers, Assistant Dean for Translational Research, Yale School of Medicine; deputy director, Yale Cancer Center; chief, Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the significance of the FDA approval of adjuvant pembrolizumab (Keytruda) in patients with non–small cell lung cancer (NSCLC).Source: OncLive
Gap Discovered in Breast Cancer Radiotherapy Recommendations for Patients Aged 70 vs 69 Years
Age-based heuristics may lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new study published by Talcott et al in the International Journal of Radiation Oncology, Biology, and Physics.Source: The ASCO Post
Doctors seeing success in HPV vaccine against cancers
(WTNH) – The only vaccine to prevent cancer has been on the market for a number of years, but doctors are now seeing the actual generation benefiting. It’s the HPV vaccine, which can prevent cervical cancer and it’s proving to be extremely effective. Doctor Elena Ratner, a gynecologic oncologist at Yale Cancer Center and Smilow Hospital says success is being seen as a result of Gardasil 9, the vaccine to prevent HPV, which is a sexually-transmitted disease that can lead to cancers.Source: WTNH
Yale’s Endocrine Neoplasia Program Is Flourishing
The Yale Multidisciplinary Endocrine Neoplasia Clinic has been treating benign and malignant diseases of the thyroid, parathyroid, adrenal, and pituitary glands since 2013. The program is a collaboration between the Department of Internal Medicine’s Section of Endocrinology & Metabolism and Yale Cancer Center and Smilow Cancer Hospital.
Yale expert familiar with procedure used on First Lady Jill Biden’s skin cancer
In light of First Lady Jill Biden's diagnosis and subsequent treatment for basal cell cancer, Yale dermatologic surgeons David Leffell, MD explains the symptoms of the condition and expands on the Moh's surgery technique used to remove the First Lady's cancer.Source: WTNH News8
Experts Study Implications of Genetic Markers in Prostate Cancer
In this video, Stacy Loeb, MD, MSc, and Veda N. Giri, MD, discuss the European Urology paper “Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention,” for which they served as coauthors. Giri is division chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer and assistant director of Clinical Cancer Genetics for Yale Cancer Center, New Haven, Connecticut. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.Source: Urology Times
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape